Monoamine oxidase inhibitors: rehabilitation from recent research?

摘要: For a long time, monoamine oxidase inhibitors (MAOIs) have been the Cinderella drugs of psycho-pharmacy. Although they were introduced just before tricyclic antidepressants (TCAs), rapidly became second-line treatments. Several factors contributed to this, in particular dietary restrictions, scattered reports death from overdose and/or toxic interactions, and unfavourable on efficacy phenelzine depression from, among others, Medical Research Council trial (1965). number years afterwards, prescription these was limited few enthusiasts. More recently, however, their popularity has increased owing firstly re-evaluation effectiveness tricyclic-resistant anxiety disorders, secondly growing awareness exaggerated claims made about dangerousness (Pare, 1985).